首页> 外文学位 >Identification and characterization of novel inhibitors of Plasmodium falciparum hemozoin formation.
【24h】

Identification and characterization of novel inhibitors of Plasmodium falciparum hemozoin formation.

机译:鉴定和表征恶性疟原虫恶唑菌素形成的新型抑制剂。

获取原文
获取原文并翻译 | 示例

摘要

After hundreds of years of scientific research, drug development and attempts at vector control, malaria still poses an enormous public health burden. One million fatalities were reported in 2006 with 91% of malaria deaths occurring in Africa and primarily in children under five years old. During its intraerythrocytic stage, the causative parasite, Plasmodium falciparum , metabolizes hemoglobin and releases toxic heme, which is neutralized by biologically controlled biomineralization (BCM) into a crystal known as hemozoin. Inhibition of this process is thought to be one of the most important drug targets in the malaria parasite, putatively the target of the quinoline antimalarials including chloroquine and amodiaquine.;We've developed a 384-well microtiter plate in vitro high throughput screen (HTS) to detect small molecules that disrupt heme crystallization, the cell free heme crystallization screen (CFHCS). This colorimetric assay requires no parasites or parasite-derived reagents and no radioactive materials. Seventeen compounds were identified from a screen of 16,000 small molecules that both inhibit heme crystallization in the CFHCS and inhibit P. falciparum growth in a separate HTS.;We've conducted a series of experiments to determine if the seventeen CFHCS hits inhibit P. falciparum growth by inhibiting heme crystallization, including heme binding assays, structure activity relationship studies, investigations of drug sensitivity in multidrug resistant parasites and experiments to determine if hemoglobin protease inhibitors antagonize the activity of the CFHCS hits. Additionally, we conducted phenotypic studies to determine if these compounds changed parasite morphology, especially the morphology of the hemozoin crystal and parasite food vacuole. Each of these assays has been previously described to support the mechanism of action of the quinoline antimalarials. Through these experiments we were able to rule out BCM as the mechanism of action of at least one compound and provide strong evidence to support this mechanism for nine compounds. Our finding also have interesting implications for the development of drugs which act by inhibiting BCM, one of the most important drug targets in the malaria parasite.
机译:经过数百年的科学研究,药物开发和媒介控制的尝试,疟疾仍然构成巨大的公共卫生负担。据报道,2006年有100万人死亡,其中91%的疟疾死亡发生在非洲,主要是五岁以下儿童。在其红细胞生成阶段,致病性寄生虫恶性疟原虫代谢血红蛋白并释放出毒性血红素,该血红素被生物控制的生物矿化(BCM)中和成晶体,称为血红素。认为抑制该过程是疟原虫中最重要的药物靶标之一,推定是包括氯喹和阿莫二喹在内的喹啉抗疟药的靶标。我们已经开发了一种384孔微量滴定板体外高通量筛选(HTS) ),以检测破坏血红素结晶的小分子,无细胞血红素结晶筛选(CFHCS)。这种比色测定不需要寄生虫或寄生虫衍生的试剂,也不需要放射性物质。从16,000个小分子中筛选出17种化合物,这些分子既抑制CFHCS中的血红素结晶,又抑制单独的HTS中的恶性疟原虫生长。我们已经进行了一系列实验,以确定17种CFHCS命中是否抑制恶性疟原虫。通过抑制血红素结晶来生长,包括血红素结合测定,结构活性关系研究,对多药耐药性寄生虫的药物敏感性研究以及确定血红蛋白蛋白酶抑制剂是否拮抗CFHCS命中活性的实验。此外,我们进行了表型研究,以确定这些化合物是否改变了寄生虫的形态,尤其是血红蛋白晶体和寄生虫食物液泡的形态。先前已经描述了这些测定中的每一种以支持喹啉抗疟药的作用机理。通过这些实验,我们可以排除BCM是至少一种化合物的作用机理,并提供了有力的证据来支持9种化合物的这种作用机理。我们的发现对开发通过抑制BCM起作用的药物也具有有趣的意义,BCM是疟疾寄生虫中最重要的药物靶标之一。

著录项

  • 作者

    Rush, Margaret Andrews.;

  • 作者单位

    Harvard University.;

  • 授予单位 Harvard University.;
  • 学科 Biology Molecular.;Biology Parasitology.;Health Sciences Public Health.
  • 学位 Ph.D.
  • 年度 2009
  • 页码 187 p.
  • 总页数 187
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 11:37:52

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号